← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Serpin Pharma, Llc
Manassas, VA
$2,194,361
Total funding
4
Grants
Funding over time
peak $838.7K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,194,361 · 4
By mechanism
R44$1,464,067 · 1
R43$730,294 · 3
Investigators at Serpin Pharma, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Novel LRP1 Agonist, SP16, as a Therapeutic Treatment in Preventing Chemotherapy-Induced Peripheral Neuropathy$838,708
R44 · FY2024 · CA
A Novel LRP1 Agonist, SP16, as a Therapeutic Treatment in Preventing Chemotherapy-Induced Peripheral Neuropathy$625,359
R44 · FY2025 · CA
Pre-clinical validation of Phase II peptide LRP-1 agonist to treat and prevent chemotherapy induced peripheral neuropathy.$398,816
R43 · FY2022 · CA
Development of a new anti-inflammatory peptide for treatment of type II diabetes$188,508
R43 · FY2014 · DK
Development of new anti-inflammatory peptides for treatment of type I diabetes$142,970
R43 · FY2013 · DK